Abstract：
Management of cancer is challenging due to non-targeting and high side effect issues. Drug repurposing is an innovative method for employing medications for other disease therapy in addition to their original use. Simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitor, is a lipid-lowering drug that is being studied for the treatment of cancer in various in vitro and in vivo models. Nanotechnology offers a potential platform for incorporation of drugs with enhanced pharmaceutical (solubility, release characteristics, stability, etc.) and biological characteristics (targeting, pharmacokinetic, pharmacodynamic). Utilizing a variety of resources such as Scopus, Springer, Web of Science, Elsevier, Bentham Science, Taylor & Francis, and PubMed, a thorough literature search was carried out by looking through electronic records published between 2003 and 2024. The keywords used were simvastatin, drug repurposing, anti-cancer simvastatin, pharmaceutical properties of simvastatin, simvastatin nanoformulations, simvastatin patents, clinical trials, etc. Numerous articles were looked for, filtered, checked out, and incorporated. Pure simvastatin has been researched as a repurposed medication for the treatment of cancer in several in vitro and in vivo models, such as carcinoma of the lung, colon, liver, prostate, breast, and skin. Simvastatin also incorporated into different nanocarriers (nanosuspensions, microparticles/nanoparticles, liposomes, and nanostructured lipid carriers) and showed improvement in solubility, bioavailability, drug loading, release kinetics, and targeting. Clinical trial and patent reports suggest potential of simvastatin in cancer therapy. The preclinical studies of pure simvastatin in in vitro and in vivo models showed the potential for its ability to inhibit cancer cell growth and further incorporation into nanoformulations strengthened its preclinical and pharmaceutical characteristics.
摘要：
由于非靶向和高副作用问题,癌症的管理是具有挑战性的。药物再利用是一种创新的方法，除了原始用途外，还可以将药物用于其他疾病治疗。辛伐他汀,一种3-羟基-3-甲基戊二酰辅酶-A还原酶抑制剂，是一种降脂药，正在各种体外和体内模型中研究用于治疗癌症。纳米技术为药物与增强的药物（溶解度，释放特性，稳定性,等。)和生物学特性(靶向，药代动力学，药效学)。利用各种资源，如Scopus，Springer,WebofScience,Elsevier,BenthamScience,泰勒和弗朗西斯，和PubMed,通过查看2003年至2024年之间发布的电子记录，进行了全面的文献检索。使用的关键词是辛伐他汀，药物再利用,抗癌辛伐他汀,辛伐他汀的药物特性，辛伐他汀纳米制剂，辛伐他汀专利，临床试验,等。寻找了许多文章，过滤，退房,并合并。纯辛伐他汀已被研究作为一种用于治疗癌症的药物，在几个体外和体内模型，比如肺癌，结肠,肝脏,前列腺,乳房,和皮肤。辛伐他汀还掺入不同的纳米载体(纳米悬浮液，微粒/纳米颗粒，脂质体，和纳米结构的脂质载体），并显示出溶解度的改善，生物利用度，药物装载，释放动力学，和瞄准。临床试验和专利报告表明辛伐他汀在癌症治疗中的潜力。纯辛伐他汀在体外和体内模型中的临床前研究显示了其抑制癌细胞生长和进一步掺入纳米制剂的能力增强了其临床前和药学特征的潜力。
